Company Overview and News


Add SGYPW
to your dashboard

Headline News

BRIEF-CVI Investments reports a 7.9 pct passive stake in Synergy Pharmaceuticals as of Nov 13, 2017

5h reuters
* CVI Investments Inc reports a 7.9 percent passive stake in Synergy Pharmaceuticals Inc as of November 13, 2017 - SEC Filing‍​ Source text: (bit.ly/2A4qbNI) Further company coverage: (240-0)

SGYP / Synergy Pharmaceuticals, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

6h fintel.io
Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) has 147 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 149,900,775 shares. Largest shareholders include Paulson & Co. Inc., BlackRock Inc., Vanguard Group Inc, Orbimed Advisors Llc, and State Street Corp. (283-3)

An Overview of Trulance: Synergy Pharmaceuticals’ First Commercialized Drug

2017-11-21 marketrealist
Since its launch, Synergy Pharmaceuticals’ (SGYP) Trulance sales have been steadily rising. According to Synergy, in 3Q17, more than 25,000 prescriptions were filled for the drug, representing a 105% rise over prescription fills in 2Q17. A total of nearly 38,000 prescriptions have been filled since the launch of Trulance in March 2017. (244-1)

Inside Synergy Pharmaceuticals: Your Investor Overview

2017-11-21 marketrealist
Synergy Pharmaceuticals (SGYP) is a biopharmaceutical company focused on developing drugs for GI (gastrointestinal) diseases like CIC (chronic idiopathic constipation), IBS-C (irritable bowel syndrome with constipation), and opioid-induced constipation and ulcerative colitis. According to Synergy, it’s estimated that ~33 million people suffer from CIC and 12 million people suffer from IBS-C in the US. (240-0)

Synergy Pharmaceuticals: What Will It Take To Rebound?

2017-11-21 seekingalpha
The need for a new capital raise became evident upon inspection of the company’s latest SEC filing, though it was poorly highlighted by management. (240-2)

Synergy Pharmaceuticals: Dissecting 3rd Quarter Cash Flow And Looking Forward

2017-11-18 seekingalpha
They had about $118 million in cash at 9/30/2017, plus net proceeds about $53 million from the recent equity offering. (240-2)

Tracking John Paulson's Paulson & Company Portfolio - Q3 2017 Update

2017-11-18 seekingalpha
Paulson & Company's largest three positions are the SPDR Gold ETF, Shire plc, and Mylan NV. (1155-10)

Synergy Pharmaceuticals: Balancing Trust With Value

2017-11-17 seekingalpha
Due to a loan which only disburses itself in tranches if Synergy jumps difficult hurdles, further dilution, baring some event, seems likely. (240-1)

Is Synergy Pharmaceuticals A Buy?

2017-11-16 seekingalpha
On November 13th, Synergy announced a financing priced below market with a full warrant that surprised investors. (240-3)

Synergy Pharmaceuticals: How To Destroy Shareholder Value

2017-11-15 seekingalpha
It takes more than have a successful best of breed drug and beating quarterly estimates to succeed in the small biopharma space. (327-2)

Your Daily Pharma Scoop: Portola Ahead Of Catalysts, AstraZeneca Gets 2 FDA Approvals, GW Pharmaceuticals' Price Target Lowered

2017-11-15 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (1487-9)

Your Daily Pharma Scoop: Portola Ahead Of Catalysts, AstraZeneca Gets Two FDA Approvals, GW Pharmaceuticals' Price Target Lowered

2017-11-15 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (1487-2)

Kinder Morgan, AK Steel Tumble into Wednesday’s 52-Week Low Club

2017-11-15 247wallst
November 15, 2017: Here are four stocks trading with heavy volume among 179 equities making new 52-week lows in Wednesday’s session. On the NYSE decliners led advancers by about 3 to 2 and on the Nasdaq, decliners led advancers by roughly the same ratio. (287-0)

General Electric, Synergy Pharma Stuck Again in Tuesday’s 52-Week Low Club

2017-11-14 247wallst
November 14, 2017: Here are four stocks trading with heavy volume among 170 equities making new 52-week lows in Tuesday’s session. On the NYSE decliners led advancers by about 3 to 2 and on the Nasdaq, decliners and advancers by less than 4 to 3. (333-3)

Synergy Pharmaceuticals: A Misjudged Secondary Offering

2017-11-14 seekingalpha
Synergy announced Monday that it would raise $56 million in a secondary offering; the market reacted poorly to news. (240-5)

CUSIP: 871639118